Abstracts tagged "Antiphospholipid antibodies"

Abstract Number: 166 • 2018 ACR/ARHP Annual Meeting
Superior Sensitivity for Detection of Primary Antiphospholipid Syndrome By a 9-Test Panel in Patients with Deep Venous Thrombosis, Pulmonary Embolism, and Stroke or Transient Ischemic Attack
Konrad Dziamski¹, Katalin Banki² and Andras Perl³, ¹Rheumatology, SUNY Upstate Medical University, Syracuse, NY, ²Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, ³Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by thrombotic events mediated by antiphospholipid antibodies (aPL). Most patients have primary APS (PAPS), while a significant minority has…
Abstract Number: 167 • 2018 ACR/ARHP Annual Meeting
Recurrent Thrombosis in Patients with Antiphospholipid Antibodies Following an Initial Venous or Arterial Thromboembolic Event
Tom Ortel¹, Sreelatha Meleth², Diane Catellier², Mark Crowther³, Doruk Erkan⁴, Paul R. Fortin⁵, David Garcia⁶, Nana Haywood², Steven R. Levine⁷, Michael J. Phillips² and Nedra Whitehead², ¹Duke University, Durham, NC, ²RTI International, Research, Triangle Park, NC, ³McMaster University, Hamilton, ON, Canada, ⁴Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁵Medicine, CHU de Québec - University of Laval, Quebec, QC, Canada, ⁶Hematology, University of Washington Medical Center, Seattle, WA, ⁷Neurology, State University of New York Downstate Medical Center, Brooklyn, NY
Background/Purpose: After an initial thromboembolic event (TE), several studies reported that patients with antiphospholipid syndrome (APS) manifest a high-risk for recurrent TE. A systematic review…
Abstract Number: 168 • 2018 ACR/ARHP Annual Meeting
IgG Anti-High-Density Lipoproteins Antibodies Discriminate between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients
Irene Cecchi¹, Massimo Radin², Elena Rubini³, Ana Suárez⁴, Dario Roccatello⁵, Savino Sciascia⁶ and Javier Rodríguez-Carrio⁷, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁴Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁷Bone and Mineral Research Unit, Instituto Reina Sofía de Investigación Nefrológica, REDinREN del ISCIII, Hospital Universitario Central de Asturias, Oviedo, Spain
Background/Purpose: Reliable biomarkers for risk stratification in Antiphospholipid Syndrome (APS) are still lacking. Anti-high-density lipoproteins antibodies (anti-HDL) showed promising results in predicting the development of…
Abstract Number: 170 • 2018 ACR/ARHP Annual Meeting
Predictive Value of Antiphospholipid Antibodies in the Acute Phase of Deep Vein Thrombosis
Katja Perdan Pirkmajer¹, Anja Boc², Saša Čučnik³, Alenka Mavri⁴, Polona Žigon³, Eva Podovsovnik⁵, Monika Štalc⁶, Nina Vene⁷ and Ales Ambrozic⁸, ¹Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Faculty of Medicine, Institute of Anatomy, University of Ljubljana, Ljubljana, Slovenia, ³University Medical Centre Ljubljana, Department of Rheumatology, Ljubljana, Slovenia, ⁴University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁵Faculty for Tourism Studies, University of Primorska, Portoroz, Slovenia, ⁶Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁷Department of Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁸Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
Background/Purpose: Deep vein thrombosis (DVT) is frequent and potentially life threatening disease with tendency to reoccur. Anticoagulant treatment of the first episode of DVT usually…
Abstract Number: 173 • 2018 ACR/ARHP Annual Meeting
The Efficacy of Treatment with Low Dose Aspirin and Low Molecular Weight Heparin in Pregnant Women with Criteria Anti-Phospholipid Antibodies
Cecilia B. Chighizola¹, Francesca Pregnolato², Maria Gabriella Raimondo³, Chiara Comerio⁴, Laura Trespidi⁵, Maria Orietta Borghi⁶, Maria Gerosa⁷, Barbara Acaia⁸, Wally Ossola⁵, Enrico Ferrazzi⁸, Alessandro Bulfoni⁹ and Pier Luigi Meroni¹⁰, ¹Rheumatology, Istituto Auxologico Italiano, University of Milan, Milan, Italy, ²Istituto Auxologico Italiano, Cusano Milanino, Italy, ³University of Milan, Istituto Ortopedico Gaetano Pini, Milan, Italy, ⁴University of Milan, Milan, Italy, ⁵Department of Obstetrics and Gynaecology, Fondazione Policlinico, Mangiagalli e Regina Elena, Milan, Italy, ⁶University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁷Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ⁸Department of Obstetrics and Gynaecology, Fondazione Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy, ⁹Division of Obstetrics and Gynaecology, Humanitas S. Pio X, Milan, Italy, ¹⁰Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Italy
Background/Purpose: Anti-phospholipid antibodies (aPL) are the biomarkers of anti-phospholipid syndrome (APS), a systemic autoimmune condition characterized by thrombosis and/or pregnancy morbidity (PM). The aim of…
Abstract Number: 852 • 2018 ACR/ARHP Annual Meeting
Antigenic Property of Prothrombin/HLA-DR Complex on Procoagulant Cells in Patients with Antiphospholipid Syndrome
Naoki Ohnishi¹, Yuichiro Fujieda¹, Ryo Hisada¹, Hiroyuki Nakamura¹, Masaru Kato¹, Kenji Oku¹, Toshiyuki Bohgaki¹, Olga Amengual¹, Shinsuke Yasuda¹, Hisashi Arase² and Tatsuya Atsumi¹, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Department of Immunochemistry, Research Institute for Microbial Disease, Osaka University, Suita, Japan
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by thrombosis and/or pregnancy morbidity and the presence of antiphospholipid antibodies (aPL). Phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT) recognize the phosphatidylserine/prothrombin…
Abstract Number: 853 • 2018 ACR/ARHP Annual Meeting
Enhanced Type I Interferon Gene Signature in Primary Antiphospholipid Syndrome: Association with Earlier Disease Onset and Preeclampsia
Michelle Lopes¹, Giovana Torrezan², Ana Paula Gandara¹, Eloisa Olivieri³, Iana Nascimento¹, Erica Okazaki⁴, Eloisa Bonfa⁵, Dirce Carraro⁶ and Danieli Andrade¹, ¹Rheumatology, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ²Genomics and Molecular Biology Laboratory, AC Camargo Cancer Center, São Paulo, Brazil, ³Macromolecules Laboratory, AC Camargo Cancer Center, São Paulo, Brazil, ⁴Hemathology, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁶Division of Genomic Diagnostics, AC Camargo Cancer Center, São Paulo, Brazil
Background/Purpose: Primary antiphospholipid syndrome (PAPS) is an autoimmune vasculopathy mediated by autoantibodies with thrombosis as its main clinical manifestation. The presence of antiphospholipid antibodies, while…
Abstract Number: 1857 • 2018 ACR/ARHP Annual Meeting
Low Molecular Weight Heparin and Aspirin Combination Therapy Modulates Th1/Th2 Cell Imbalance in Pregnant Patients with Antiphospholipid Antibody-Associated Recurrent Pregnancy Loss
Meiying Wang^1,2, Peng Zhang³, gengmin zhou¹, jiyang lv¹, chengshan guo⁴ and Qingwen Wang¹, ¹Rheumatology and Immunology, Peking University Shenzhen Hospital, shenzhen, China, ²Rheumtology, David Geffen school of Medicine at UCLA, Los Angeles, CA, ³SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY CHINESE ACADEMY OF SCIENCES, shenzhen, China, ⁴Rheumatology and Immunology, The people's Hospital of Bao’an District Shenzhen City., shenzhen, China
Background/Purpose: Type 1/type 2 T helper (Th1/Th2) cells and their cytokines are implicated in the pathogenesis of autoimmune diseases[1]; however, their roles in antiphospholipid antibody-associated…
Abstract Number: 2414 • 2018 ACR/ARHP Annual Meeting
The Global Antiphospholipid Syndrome Score in Women with Systemic Lupus Erythematosus and Adverse Pregnancy Outcomes
Karen Schreiber¹, Massimo Radin², Irene Cecchi³, Elena Rubini⁴, Dario Roccatello⁵, Søren Jacobsen⁶, Maria Jose Cuadrado⁷ and Savino Sciascia⁸, ¹Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶University of Copenhagen, Copenhagen, Denmark, ⁷Clinica Universidad de Navarra, Madrid, Spain, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) and antiphospholipid antibodies (aPL) are associated with pregnancy complications. Methods: 143 women ever pregnant with SLE who presented in our…
Abstract Number: 2428 • 2018 ACR/ARHP Annual Meeting
Correlation between Antibodies to the Phosphotidylserine/Prothrombin Complex (aPS/PT) and Anti-β2glycoprotein-1-Domain 1 (anti-β2GP1-D1) and Vascular Thrombosis (VT) and/or Pregnancy Morbidity (PM)
Eric Campbell¹, Tania Pannu¹, Marvin J. Fritzler², Michelle Jung³, Claire Barber⁴, Yvan St. Pierre⁵ and Ann E. Clarke², ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁴Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: aPS/PT is considered to be a risk factor for vascular thrombosis (VT) and/or pregnancy morbidity (PM). Anti-β2GP1-D1 is potentially superior to anti-β2GP1 in predicting…
Abstract Number: 2635 • 2018 ACR/ARHP Annual Meeting
Combined Panel of Nine Tests Has the Greatest Sensitivity but the Lowest Specificity to Detect Antiphospholipid Antibody Syndrome in Patients with Systemic Lupus Erythematosus
Saika Sharmeen¹, Katalin Banki² and Andras Perl³, ¹Medicine, State University of New York Upstate Medical University, Syracuse, NY, ²Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, ³Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Antiphospholipid antibody syndrome (APS) is an autoimmune hypercoagulable state caused by antiphospholipid antibodies (aPL) which represent a diagnostic criterion and underlie significant comorbidities in…
Abstract Number: 156 • 2018 ACR/ARHP Annual Meeting
Assessing the Role of Ascvd Score in Primary Thrombosis Prophylaxis Strategy Among Asymptomatic Antiphospholipid Antibody Carriers
Yu Zuo¹, Akrithi Udupa², Jennifer Fan¹, Una E. Makris¹, David Karp^1,3 and Yu-min Shen¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ³Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Primary thrombosis prophylaxis among asymptomatic antiphospholipid antibody (aPL) carriers is challenging. The presence of aPL does not always lead to thromboembolic events. Additional factors…
Abstract Number: 2641 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Could Modulate S100 Proteins Expression, Which Reflect the Activity of Lupus Nephritis or Skin Lesion, in Systemic Lupus Erythematosus Patients with Low Disease Activity
Risa Wakiya, Tomohiro Kameda, Shusaku Nakashima, Hiromi Shimada, Mikiya Kato, Taichi Miyagi, Kiyo Ueeda and Hiroaki Dobashi, Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: To find the effect of HCQ treatment on expression of S100 proteins which were reported to reflect the activity of SLE including lupus nephritis…
Abstract Number: 7 • 2017 ACR/ARHP Annual Meeting
Predictive Value for Thrombosis of Double or Triple Positivity in Secondary APS Depends on the Component Assays and the Type of Thrombosis
Michelle Petri¹, Daniel Goldman² and Laurence S Magder³, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: The lupus anticoagulant (LAC) is individually the antiphospholipid antibody (aPL) most associated with thrombotic risk in both primary and secondary APS. Anticardiolipin (aCL) and…
Abstract Number: 9 • 2017 ACR/ARHP Annual Meeting
Renal Protective Effect of Antiplatelet Therapy in Antiphospholipid Antibody-Positive Lupus Nephritis Patients without the Antiphospholipid Syndrome
Hironari Hanaoka¹, Tomofumi Kiyokawa¹, Harunobu Iida¹, Yukiko Takakuwa¹, Takahiro Okazaki², Hidehiro Yamada³, Shoichi Ozaki⁴ and Kimito Kawahata¹, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan, ⁴Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. Since antiphospholipid syndrome (APS) is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].